

Abstract ID Number	Poster Number	Session Date	Session Time	Session Room	Venue Name and Location	Abstract Title	Selected Abstracts
100214	P-001	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Development of a deep learning-based algorithm for fat quantification using proton density fat fraction maps in liver MRI	
100081	P-002	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Reconstructing Exosomal Biomechanical Signatures from RNA Profiles to Predict Hepatocellular Carcinoma Progression: A Deep Learning-Based Approach	★
100213	P-003	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	The consequently annual prediction of HCC recurrence after partial hepatectomies with artificial intelligence	
100008	P-004	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Using Machine Learning to Predict High-Risk Populations Among Hepatocellular Carcinoma Patients	
100057	P-005	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Validation for the Efficacy of AI Platforms on Liver Cancer Treatment Strategies	
100060	P-006	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	A Machine Learning Model for Predicting Hepatocellular Carcinoma in Patients with MASLD	
100115	P-007	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Withdrawal	
100204	P-008	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Tumor Budding Predicts Poor Survival in Hepatocellular Carcinoma Patients Treated with Neoadjuvant/Conversion Therapy: A Cohort Study Using ITBCC Criteria	★
100229	P-009	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Analysis of Antidrug Antibodies (ADA) to Camrelizumab in CARES-310: The Study of Camrelizumab + Rivoceranib in Unresectable Hepatocellular Carcinoma (uHCC)	
100108	P-010	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	The Slope of Reduced Serum PIVKA-II Predicts The Responses of Immunotherapy in Hepatocellular Carcinoma Patients	
100228	P-011	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Association of Alpha-fetoprotein and Clinical Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with Camrelizumab + Rivoceranib vs Sorafenib (CARES-310)	
100145	P-012	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Using Next-Generation Sequencing to Predict Anti-PD-(L)1 Response in Hepatocellular Carcinoma	
100125	P-013	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Exosomal miR-30a-5p for Predicting Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma	
100152	P-014	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	CT-derived Body Composition as a Prognostic Biomarker in Early-Stage Hepatocellular Carcinoma: Insights from Volumetric and Single-Slice Assessments	
100068	P-015	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Liver Stiffness by VCTE Predicts Hepatic Decompensation and Differential Efficacy of Atezolizumab-Bevacizumab versus TKIs in Advanced Hepatocellular Carcinoma	
100189	P-016	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Impact of Interleukin-6 and -8 on Treatment Efficacy of Bevacizumab plus ICIs and Interventional Therapy in patients with unresectable HCC	
100066	P-017	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	PVR Expression Associated with Unique Tumor Microenvironment in Hepatocellular Carcinoma	
100225	P-018	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Distribution, density and composition of tertiary lymphoid structures predict clinical outcome in liver cancer	
100002	P-019	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Magnetic Resonance Imaging Radiomics for Predicting Hepatocellular Carcinoma Recurrence Following Resection or Ablation: A Systematic Review and Meta-analysis	
100129	P-020	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Development of Pathological Prediction Models for Extrahepatic Metastasis of Hepatocellular Carcinoma	
100158	P-021	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Usefulness of perioperative peripheral blood GPC3-positive circulating tumor cells in subclassification of Barcelona Clinic Liver Cancer Stage B hepatocellular carcinoma	
100188	P-022	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	The usefulness of the non-invasive scoring systems for the hepatocarcinogenesis in patients with MASLD/MASH	★
100111	P-023	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Serum full-length glypican 3 predicts therapeutic response and survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab	
100147	P-024	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Prognostic and predictive value of lymphocyte-to-monocyte transition in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab	★
100082	P-025	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Explainable Deep Learning for Ultra-Early Detection of Hepatocellular Carcinoma via Multi-Omics Integration of Single-Cell Transcriptomics and DNA Methylation Signatures	
100162	P-026	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Albumin-Butyrylcholinesterase (ABC) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma Post-hepatectomy: A Multi-Center Retrospective Cohort Study	
100169	P-027	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Tumor-Stroma Ratio as a Prognostic Indicator in HCC: Multi-Omics Insights into the Tumor Microenvironment and Prediction of Neoadjuvant Therapy Response	
100036	P-028	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	HBV DNA Level Change is Associated With Tumor Recurrence in Patients With Resected HBV related Hepatocellular Carcinoma	
100013	P-029	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	ACSL4 as a Biomarker for Assessing the Metastatic and Recurrence Propensity of Hepatocellular Carcinoma: Insights from a Multicenter Study	
100085	P-030	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Tumor-infiltrating lymphocyte abundance refines prognosis in patients with hepatocellular carcinoma	
100143	P-031	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Genomic Instability and EGFR Amplification as Mechanisms of Lenvatinib Resistance in Hepatocellular Carcinoma	
100076	P-032	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Functional and Spatial Polarization of Cancer-Associated Fibroblasts in the Tumor Microenvironment of Hepatocellular Carcinoma	
100086	P-033	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Spatially-Aware AI Framework Identifies Hypoxia-Induced Metabolic Zonation Collapse as a Driver of Immune Exclusion in Hepatocellular Carcinoma	
100107	P-034	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Patient-Derived Organotypic Tumor Spheroids Enable Rapid Drug Evaluation in Hepatocellular Carcinoma	
100148	P-035	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Dendritic Cell Mediated CD8+ T Cell Priming Prolongs Yttrium-90-radioembolisation Efficacy in Hepatocellular Carcinoma	
100183	P-036	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Charting single-cell metabolism co-evolution during metastasis	
100022	P-037	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Assessment of Shear Wave Velocity and Predictors of Liver Fibrosis Improvement in HBV-Induced Cirrhosis Treated with Tenofovir Disoproxil Fumarate	

Abstract ID Number	Poster Number	Session Date	Session Time	Session Room	Venue Name and Location	Abstract Title	Selected Abstracts
100168	P-038	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Diagnostic usefulness of point-of-care ultrasound in detecting newly developed ascites in patients with liver cirrhosis	
100172	P-039	July 12 (Sat.)	16:00-17:00	Poster Room 1	Kikusui, B1F, Main Building, Kobe Portopia Hotel	Effects of cirrhosis on long-term survival of patients with early and middle stage HBV-related hepatocellular carcinoma: a multicenter, cohort study	
100223	P-040	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Integrating CT-Based Radiomics and Machine Learning to Predict Immunotherapy Response in Advanced Hepatocellular Carcinoma	
100124	P-041	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Postoperative Recovery in Liver Disease: The Role of Caregiver Perception, Knowledge, and Attitude	
100182	P-042	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Withdrawal	
100181	P-043	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Withdrawal	
100175	P-044	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Diagnostic Accuracy and Safety of EUS-Guided Liver Biopsy in the Endoscopic Hepatology Era: A Single-Center Experience	
100106	P-045	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Identifying the high-risk group of MASH-related HCC using MR elastography	
100199	P-046	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Withdrawal	
100123	P-047	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	The Role of Radiogenomics in Early-Stage Liver Cancer Screening	
100170	P-048	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Comparative performance of gadoxetic acid-enhanced MRI and extracellular contrast agent-enhanced MRI for diagnosing subcentimeter recurrent HCC: a modified algorithm	
100101	P-049	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Detection and Characterization of Subcentimeter Hepatocellular Carcinoma: A Comparison of Gadoxetic Acid-Enhanced and Extracellular Contrast Agent-Enhanced MRI	
100201	P-050	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Hepatocellular Carcinoma in Southern Taiwan: Report from a Tertiary Medical Center	
100194	P-051	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Cyanotoxins and Metabolic-Associated Hepatocellular Carcinoma	
100047	P-052	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Prognostic Impact of Diabetes and Hypertension on Hepatocellular Carcinoma Survival: A 15-Year Registry-Based Analysis	
100128	P-053	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	An Evaluation of Long-Term Fasting Effects on Preoperative and Postoperative Outcomes in Liver Surgery	
100141	P-054	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Predictive Value of OGTT for Hepatocellular Carcinoma in Liver Cirrhosis: A Prospective Observation	
100220	P-055	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Alcohol-related liver disease in liver transplantation	
100075	P-056	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Socioeconomic factors for poor compliance with hepatocellular carcinoma surveillance in patients with chronic hepatitis B	
100032	P-057	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	US Liver Imaging Reporting and Data System Version 2017: A Systematic Review and Meta-Analysis	
100193	P-058	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Pediatric Malignant Neoplasm of Liver; Nationwide Cohort Study of Korea	
100028	P-059	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Dose-Response Association Between Body Mass Index and the Risk of Cholangiocarcinoma	★
100120	P-060	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Risk factors and prolonged survival in liver cancer patients undergoing immunotherapy: A multivariate regression analysis	
100069	P-061	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Impact of Waiting Time Before Surgery on Survival in Bile Tract Cancer	
100114	P-062	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Withdrawal	
100118	P-063	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Aging in Place for Elderly with Liver Conditions Undergoing Laparoscopic Procedures: Informal Caregivers Roles in Maintaining Quality of Life	
100004	P-064	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Nonlinear Association Between Serum Vitamin D Status and Liver Disease Risk: A US Cohort Study	
100003	P-065	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Association of Vitamin D Deficiency on Liver Disease and Mortality: A US Cohort Study	
100127	P-066	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Impact Evaluation of Policy Interventions on Liver Disease Prevalence: Assessing the Smoking and Alcohol Regulation in Indonesia	
100087	P-067	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	The Influence of COVID-19 on Hepatocellular Carcinoma Was Investigated Using Bioinformatics and Systems Biology Techniques	
100221	P-068	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Early Detection occurrence and recurrence, Prompt Treatment, Re-treatment, Multidisciplinary Care in Long-term of hepatocellular carcinoma: Roles of modifiable medical interventions	
100208	P-069	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Hepatocellular carcinoma following direct-acting antiviral therapy in Korean patients with HBV/HCV co-infection	
100122	P-070	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Cost-Effectiveness Analysis of Laparoscopic Liver Resection (LLR): Therapeutic Efficacy and Socioeconomic Outcomes	
100088	P-071	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	The Effect of $Clostridium$ Strains on Liver Cancer	
100131	P-072	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Transcriptomic and tumor immune microenvironment profiling of steatohepatic, burned-out steatohepatic, and scirrhous hepatocellular carcinomas	
100040	P-073	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	LncRNA CDKN2B-AS1 Genetic Variants are Associated with Progression of Hepatocellular Carcinoma	
100038	P-074	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Three-dimensional vascular structure of hepatocellular carcinoma revealed by tissue clearing method and relationship with immune microenvironment	

Abstract ID Number	Poster Number	Session Date	Session Time	Session Room	Venue Name and Location	Abstract Title	Selected Abstracts
100017	P-075	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Cathepsin A is critical in regulating cell growth of hepatocellular carcinoma via stabilizing Bcl-2	
100084	P-076	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Radiation-induced SA-βGal+ Hepatoma Cells Inhibit Tumor Immunity Through Promoting Neutrophils N2 Polarization	
100138	P-077	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Reconstruction of the Metabolism of β-hydroxybutyric Acid Accelerates the Progression of Hepatocellular Carcinoma through β-hydroxybutyrylation Modification	
100033	P-078	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Distinct molecular pathways regulated by activated AKT and YAP signaling during intrahepatic cholangiocarcinoma progression	
100202	P-079	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Pathological features and metabolic risk factors associated with immune-related liver injury induced by immune checkpoint inhibitors	
100023	P-080	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Assessment of Liver Fibrosis in Alcoholic Liver Disease Using ARFI Elastography	
100071	P-081	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Iron-Corrected T1 as a Predictor of Extrahepatic Cancer Risk: A UK Biobank Study	
100061	P-082	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Obstructive Sleep Apnea	
100126	P-083	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Utility of Complete Blood Count-Derived Inflammatory Indices for Predicting Metabolic-Associated with Fatty Liver Diseases in a Korean Population	
100046	P-084	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Incidence and Management of Hepatic Immune-Related Adverse Events in Advanced Urologic Cancers Treated with Immune Checkpoint Inhibitors	
100121	P-085	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Radiotherapy Confers 5-FU Resistance in intrahepatic cholangiocarcinoma Cells	
100050	P-086	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Single-center experience of Two-step liver resection in treatment of advanced hepatic echinococcosis	
100205	P-087	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	A single arm phase II trial of tislelizumab plus adaptive chemotherapy in biliary tract cancer (BTC) patients with lymphatic metastasis	
100185	P-088	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Differentiation of Epithelioid Hepatic Angiomyolipoma from Hepatocellular Carcinoma on MR Imaging in Patients with Hepatitis B based on LI-RADS v2018	
100083	P-089	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	cGAS-STING-ARG1 Axis Drives CD8+ T Cell Dysfunction in Radiation-Induced Liver Injury	
100177	P-090	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Machine-learning algorithms for predicting hepatic steatosis grades in Chinese non-obese population	
100206	P-091	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Impact of Age on Treatment Uptake and Survival in Elderly Patients With Hepatocellular Carcinoma	
100195	P-092	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Dynamic Prognostic Nomogram for Conditional Survival in Hepatocellular Carcinoma: An Analysis from the Korea Liver Cancer Registry	
100041	P-093	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Prognostic Value of Sarcopenia on the Recurrence of Hepatic Encephalopathy	
100062	P-094	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Role of ALBI score as a predictive factor for mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization	
100063	P-095	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Comparative Prognostic Value of Albumin-Bilirubin Grade, PALBI, and MELD 3.0 in Hepatocellular Carcinoma Patients with Renal Insufficiency	
100110	P-096	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Clinical Characteristics of Progression and Prognosis in Hepatocellular Carcinoma with Underlying Alcohol-Related Liver Disease	
100211	P-097	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Prognosis of Systemic Therapy Based on Oncological Resectability Criteria	
100015	P-098	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Prognostic Value of Preoperative Osteopenia in Hepatocellular Carcinoma	
100136	P-099	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Arterial infusion chemotherapy plus apatinib in second-line therapy for hepatocellular carcinoma with extrahepatic metastasis	
100031	P-100	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Drug-eluting Beads Transcatheter Arterial Chemoembolization Plus Adebrelimab and Apatinib in Hepatocellular Carcinoma with PVTT: A Single-arm, Exploratory Trial	
100161	P-101	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	<i>Withdrawal</i>	
100074	P-102	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Yttrium-90 Combined with Donafenib and Immune Checkpoint Inhibitors for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Trial in Progress	
100090	P-103	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Safety and Efficacy of Lenvatinib ± TACE as Conversion Therapy for Potentially Resectable HCC Patients: A Double-arm, Prospective Study	
100190	P-104	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Prospective Observational Study on Systemic Therapy for Unresectable Hepatocellular Carcinoma (PRISM Study): An Update Analysis of First 1,000 patients	
100116	P-105	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Pseudo-Progression of Metastatic Hepatocellular Carcinoma in a Subject Who Received Glypican-3-targeting Engineered T Cell Therapy: Serial Imaging and Laboratory Findings	
100092	P-106	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Barbituric Acid Derivative Ameliorates MAFLD-induced Liver Cancer and Mood Disorders in Mice	
100097	P-107	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Treatment strategy for Colorectal liver metastases based on liver resection and the benefit of preoperative chemotherapy	
100160	P-108	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Impact of Initial Hepatectomy With Hilar Manipulation on Short-Term Outcomes of Repeat Hepatectomy for Recurrent Liver Cancer	
100007	P-109	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation	
100212	P-110	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Impact of Post-Hepatectomy Liver Failure on Long-Term Liver Function and Prognosis in Patients with Hepatocellular Carcinoma	
100203	P-111	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Impact of Multimodal Treatment and Conversion Surgery in Advanced Hepatocellular Carcinoma Based on BR Classification	

Abstract ID Number	Poster Number	Session Date	Session Time	Session Room	Venue Name and Location	Abstract Title	Selected Abstracts
100112	P-112	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	ABO blood type has no effect on HCC recurrence after LDLT in the Korean Organ Transplantation Registry study	
100059	P-113	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Results of Laparoscopic Versus Open Major Hepatectomy for Hepatocellular Carcinoma in a Vietnamese Tertiary Hospital: A Five-Year Retrospective Comparative Study	
100100	P-114	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	In Vivo Multi-organ Hypothermic Perfusion and Autotransplantation for Treating Tumors Invading the Superior Visceral Artery Segment of Abdominal Aorta	
100167	P-115	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Association between cisterna chyli diameter and perioperative factors in patients undergoing hepatectomy for hepatocellular carcinoma	
100166	P-116	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Cytoreductive surgery for advanced Hepatocellular carcinoma with macrovascular thrombosis unresponsive to systemic therapy: A case report.	
100119	P-117	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Advances and Challenges in Liver Transplantation: The Laparoscopic Potential for Intraoperative Risk Reduction and Recovery improvements.	
100163	P-118	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Evaluation of Nutritional Risk Assessment Methods for Hepatectomy in Hepatocellular Carcinoma	
100164	P-119	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	A Case of Successful Conversion Hepatectomy Following Durvalumab plus Tremelimumab Therapy under Nasogastric Feeding for Advanced Vp4 Hepatocellular Carcinoma	
100065	P-120	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Network meta-analysis of prognostic performance of expanded criteria for liver donors with hepatocellular carcinoma	
100159	P-121	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Analysis of the Relation between Tumor Location and Surgical Outcomes in Hepatocellular Carcinoma	
100117	P-122	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Comparative long-term outcomes of minimally invasive hepatectomy and open hepatectomy: How health behaviors could affect the overall qol?	
100196	P-123	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Impact of tumor size on liver regeneration after hepatectomy	
100056	P-124	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Efficacy and safety of adefrelimab combined with lenvatinib as neoadjuvant therapy for resectable hepatocellular carcinoma: a single-arm, phase II study	
100215	P-125	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Laparoscopic right posterior sectionectomy using the anterior approach for huge hepatocellular carcinoma	
100025	P-126	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Validation of 3 borderline resectable hepatocellular carcinoma models	
100180	P-127	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Efficacy and Safety of Preoperative Neoadjuvant Systemic Therapy for cNLC Stage Ib - IIIa Hepatocellular Carcinoma: A Retrospective Study	
100176	P-128	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Clinical factors Associated with Resection Rate and Survival After Conversion Therapy with HAIC Combined with Targeted-Immunotherapy for Unresectable HCC	
100178	P-129	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Preoperative circulating tumor cells indicate microvascular invasion and dynamical detection indicate the early recurrence of hepatocellular carcinoma	
100043	P-130	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Liver Resection Using In Situ Hypothermic Portal Perfusion Without Venovenous Bypass for the Treatment of Bismuth Type IV Hilar Cholangiocarcinoma	
100156	P-131	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Characteristics and risk factors of extrahepatic recurrence after hepatectomy of hepatocellular carcinoma without intrahepatic hepatocellular carcinoma: A multi-institutional observational study	
100133	P-132	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Liver transplantation after radiotherapy-antiangiogenesis-immune checkpoint blockade combination therapy in hepatocellular carcinoma with major PVTT: A propensity score matching analysis	
100089	P-133	July 12 (Sat.)	16:00-17:00	Poster Room 2	Nunobiki & Nunobiki, B1F, Main Building, Kobe Portopia Hotel	Extrahepatic recurrence after surgical resection of hepatocellular carcinoma without intrahepatic recurrence: A multi-institutional observational study	
100155	P-134	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	TACE Alone vs Combination Therapies in Hepatocellular Carcinoma: A Pilot Study Based on Real Life Data in Unselected Patients	
100006	P-135	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	UCHL1 Hijacks Tolerogenic Dendritic Cell Maturation and Promotes mregDC-Treg Crosstalk to Nullify Checkpoint Blockade	
100227	P-136	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Camrelizumab + Rivoceranib vs Sorafenib (CARES-310) as First-line Treatment for Patients with Unresectable Hepatocellular Carcinoma of Non-viral and Viral Etiology	
100187	P-137	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Targeted and Immune Checkpoint Inhibitor plus Hepatic Arterial Infusion Chemotherapy for Initially Diagnosed Unresectable Hepatocellular Carcinoma	
100099	P-138	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Efficacy and safety of first-line atezolizumab plus bevacizumab versus lenvatinib plus pembrolizumab for unresectable hepatocellular carcinoma: a nationwide multicenter study	
100165	P-139	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Peripheral Blood Inflammatory Score Using a Cytokine Multiplex Assay Predicts Clinical Outcomes in Patients Treated with Atezolizumab-Bevacizumab for Unresectable HCC	
100217	P-140	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Atezolizumab plus Bevacizumab with or without Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: Real-World Evidence from a Multicenter Study	
100051	P-141	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Quadruple Therapy (TACE-HAIC + TKIs + PD-1 Inhibitors) for Advanced HCC with Portal Vein Tumor Thrombus: Efficacy and Safety	
100001	P-142	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Subset of CPS 7 Shows Comparable Survival Outcomes to CPS 6 in Hepatocellular Carcinoma Patients Treated with Atezolizumab and Bevacizumab	
100020	P-143	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Developing Novel Phytochemical-Derived Zingerone Nanoparticles as A Potent Chemopreventive Strategy for Human Hepatocellular Carcinoma	
100103	P-144	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Anti-angiogenic Adverse Events Predict for Improved Survival with Atezolizumab-Bevacizumab in Patients with Advanced Hepatocellular Carcinoma	
100018	P-145	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Utility of Alpha-Fetoprotein and PIVKA-II kinetics as radiologic and survival outcomes in patients with unresectable hepatocellular carcinoma undergoing immunotherapy	
100019	P-146	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	CRAFTY-100 RULE score as a predictive factor of survival outcome in patients with unresectable hepatocellular carcinoma undergoing immunotherapy	
100024	P-147	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Development and Validation of a Risk Prediction Model for Patients with Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab	
100035	P-148	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Glycemic control determines the therapeutic responses to immunotherapy in diabetic patients with hepatocellular carcinoma	

Abstract ID Number	Poster Number	Session Date	Session Time	Session Room	Venue Name and Location	Abstract Title	Selected Abstracts
100207	P-149	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Efficacy and Safety of TACE-HAIC-MTTs-ICIs vs. TACE-MTTs-ICIs in Hepatocellular Carcinoma: Prognostic Analysis of Serum AFP Dynamics	
100064	P-150	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Effectiveness and Safety of Atezolizumab Combined with Bevacizumab in Patients with Hepatocellular Carcinoma: A Single-Center Retrospective Study in Vietnam	
100067	P-151	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	From Palliation to Cure: Curative Resection of Advanced HCC Achieved through Selective Internal Radiation Therapy Conversion	
100105	P-152	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Tremelimumab plus Durvalumab in Participants with Unresectable Hepatocellular Carcinoma (uHCC) from Mainland China in the Phase 3 HIMALAYA Study	
100016	P-153	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Two complete-response cases to Lenvatinib for recurrence after radical hepatectomy against hepatocellular carcinoma with massive tumor thrombus.	
100157	P-154	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Outcomes and Indications of Curative Conversion Therapy After Immunotherapy	
100216	P-155	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Efficacy and Safety of Atezolizumab Plus Bevacizumab in Elderly Patients with Unresectable Hepatocellular Carcinoma : A Single-Center Retrospective Analysis	
100218	P-156	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Differences in Regulatory Approvals and Guidelines for Durvalumab and Tremelimumab Combination Therapy and Durvalumab Monotherapy in Hepatocellular Carcinoma Across Countries	
100153	P-157	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	The different of surgical treatment or transcatheter arterial chemoembolization combined with systemic treatment for spontaneously ruptured hepatocellular carcinoma	
100179	P-158	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	A Real-World Study of Lenvatinib + PD-1 + GEMOX in the First-Line of Cholangiocarcinoma	
100137	P-159	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Impact of endoscopic retrograde cholangiopancreatography in hepatocellular carcinoma patients with bile duct invasion receiving atezolizumab plus bevacizumab	
100055	P-160	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Bufalin Induces Immunogenic Cell Death and Synergizes with Doxorubicin to Suppress Hepatocellular Carcinoma	
100171	P-161	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Comparison of neoadjuvant therapy plus surgery, surgery alone, and surgery plus adjuvant therapy on prognosis in patients with hepatocellular carcinoma	
100154	P-162	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Comparison of Treatment Efficacy and Safety Profile of Atezolizumab Plus Bevacizumab in BCLC B and C Patients with Hepatocellular Carcinoma	
100140	P-163	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Metabolic Dysfunction-Associated Steatotic Liver Disease Increases Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Systematic Review and Meta-Analysis	
100079	P-164	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Long-Term Kidney Function in Chronic Hepatitis B Patients Treated with High Genetic Barrier Agents: Results from a Korean Nationwide Study	
100224	P-165	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	<i>Withdrawal</i>	
100027	P-166	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Effect of diabetes on the risk of fibrosis progression in patients with chronic hepatitis B	
100077	P-167	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Risk Factors for Hepatocellular Carcinoma After Sustained Virologic Response in Patients Treated with Glecaprevir/Pibrentasvir: A Prospective Cohort Study	
100026	P-168	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Aspirin use and risk of HCC and gastrointestinal bleeding in patients with HBV-related cirrhosis: A landmark analysis	
100192	P-169	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Individual and combined CMRFs on liver-related outcomes in CHC patients with SLD after curative antiviral therapy	
100021	P-170	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Evaluation of Diep Ha Chau (DHC) Combined with Tenofovir Disoproxil Fumarate (TDF) in the Treatment of Chronic Hepatitis B	
100226	P-171	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Efficacy of TACE based multimodal treatment in patients with neuroendocrine tumors involving the liver	
100132	P-172	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Radiotherapy for elderly patients with liver-confined hepatocellular carcinoma	
100073	P-173	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Combining Radiotherapy and Anti-CCR8 to Improve the Tumor Immune Microenvironment and Overcome Radioresistance in Liver Cancer	
100184	P-174	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Thermo Ablation is Reasonable for Singular Sub Centimeter Hepatocellular Carcinoma.	
100210	P-175	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Retrospective Analysis of Molecular Subtype-Driven Precision Management in Intrahepatic Cholangiocarcinoma (Large-Duct vs. Small-Duct Types)	
100135	P-176	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Long-term overall survival after hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for unresectable hepatocellular carcinoma	
100095	P-177	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Current Status and Advances of Yttrium-90 Selective Internal Radiation Therapy for Hepatocellular Carcinoma at Tsinghua Changgung Hospital	
100054	P-178	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Safety and Efficacy of Yttrium-90 Selective Internal Radiation Therapy for Massive Hepatocellular Carcinoma: A Single-Center Experience in China	
100029	P-179	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Efficacy and Safety of SIRT Combined with Low-dose HAIC, TKIs and ICIs for Unresectable Large HCC	
100039	P-180	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Refined conversion surgery treatment for liver cancer mediated by a ultra-stable lipiodol drug sustained release formula	
100093	P-181	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Feasibility Assessment of Novel Radiotherapy for Abdominal Cancer	
100102	P-182	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Tumor Burden Hepatocellular Carcinoma: a Multicenter, Retrospective, Propensity Score-Matched Study	
100222	P-183	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Why does Combination Radiotherapy with Tyrosine Kinase Inhibitors Improve Survival of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis ?	
100219	P-184	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Outcome of RFA for First Recurrence after Resection of Hepatocellular Carcinoma and Risk Factors for Recurrence after RFA	
100113	P-185	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Comparing Clinically Significant Lung Shunt Fraction in Hepatocellular Carcinoma and Cholangiocarcinoma Yttrium-90 Mapping Procedures	

Abstract ID Number	Poster Number	Session Date	Session Time	Session Room	Venue Name and Location	Abstract Title	Selected Abstracts
100030	P-186	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Survival Outcomes of Transarterial Treatment versus Systemic Therapy as Initial Treatment for Hepatocellular Carcinoma with Extrahepatic Metastasis	★
100072	P-187	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	CD44 Promotes Radiation-Induced Liver Disease via Kupffer Cell M1 Polarization and the NF- κ B Signaling Pathway	
100080	P-188	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Efficacy and safety of SIRT combined with TACE or HAIC and systemic therapy for unresectable hepatocellular carcinoma: a case series	
100104	P-189	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Multi-dimensional analysis of yttrium-90 microsphere selective internal radiation therapy in liver tumors: tumor biological differences, treatment parameters, and short-term efficacy	
100070	P-190	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Case share of HAIC plus systemic therapy in unresectable HCC aimed for conversion	
100191	P-191	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Yttrium-90 Selective Internal Radiation Therapy versus Stereotactic Body Radiation Therapy for Unresectable Hepatic Malignancies: A Retrospective Cohort Study	
100144	P-192	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	On-Demand Locoregional Therapy Benefits Survival in Patients with Unresectable Hepatocellular Carcinoma Undergoing Sorafenib or Lenvatinib Treatment	
100091	P-193	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Selective Internal Radiation Therapy Combined by Atezolizumab-Bevacizumab is a Promising Treatment for Unresectable Hepatocellular Carcinoma: A Chinese Clinical Experience	
100134	P-194	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Oleanolic acid sensitizes radiotherapy and prevents radiation-induced liver injury in hepatocellular carcinoma	
100053	P-195	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Radioembolization with 90Y-microspheres Liver Cancer Treatment: Radioactive Hepatectomy and Efficacy Evaluation : A Case Series Analysis	
100094	P-196	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Efficacy and safety of yttrium-90 (SIRT) combined with HAIC and other therapeutic in the treatment of end-stage HCC	
100052	P-197	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Surgical Resection Versus Stereotactic Body Radiation Therapy for BCLC Stage 0 Hepatocellular Carcinoma: A Propensity-Weighted Analysis	
100042	P-198	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Clinical Application of a Novel 0.035 inch Inner Diameter Microcatheter as an Intermediate Catheter in Selective Transcatheter Arterial Chemembolization	
100045	P-199	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Efficacy and Safety of SIRT in Patients with HCC as an Initial or Subsequent Treatment after Failure of Previous Treatment	
100098	P-200	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Safety and Efficacy of Yttrium-90 Selective Internal Radiation Therapy for Huge Hepatocellular Carcinoma (≥ 10 cm): a Case Series from China	
100078	P-201	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Selective Internal Radiation Downstaging Strategy HCC Beyond Milan criteria: A Chinese Retrospective Study	
100130	P-202	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Outcomes of Selective Internal Radiation Therapy with Yttrium-90 in Super-giant (≥ 15 cm) Hepatocellular Carcinoma: A Case Series	
100197	P-203	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Efficacy of Radiation Therapy and Targeted Therapy Combined with or without Immunotherapy for Lymph Node Metastases in Hepatocellular Carcinoma	
100096	P-204	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Precision Medicine-Guided Radiation Segmentectomy Using Selective Internal Radiation Therapy: Efficacy and Safety in Hepatocellular Carcinoma Patients	
100173	P-205	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Preoperative HAIC Enlarges Future Liver Remnant (FLR) in Initially Unresectable Hepatocellular Carcinoma Patients with Vp3 Tumor Thrombus	
100139	P-206	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	Standard-of-care systemic therapy with or without radiotherapy in patients with unresectable intrahepatic cholangiocarcinoma	
Late-Breaking	P-207	July 12 (Sat.)	16:00-17:00	Poster Room 3	Ikuta, B1F, Main Building, Kobe Portopia Hotel	A Structured Conversion Strategy Using RESECT-S to Identify Resectable Candidates Among Unresectable HCC Patients Receiving CAR-T Therapy	